Related Experiment Video
Updated: Jan 8, 2026

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Zervimesine, a Small Sigma‑2 Receptor Selective Modulator for Alzheimer's Disease
Isabel Iriepa1,2, Marialessandra Contino3, Carmen Abate3
1Departamento de Química Orgánica y Química Inorgánica, Instituto de Investigación Química "Andrés M. del Río" (IQAR), Universidad de Alcalá, 28805-Alcalá de Henares, Madrid, Spain.
Abstract:
Zervimesine is a small molecule, able to cross the blood-brain barrier, readily available by straightforward organic chemistry processes, showing few "off-target" effects, but displays a potent and selective S2R modulator profile. Evidence suggests Zervimesine can protect synapses and neurons by preventing the toxic effects of soluble Aβ oligomers.
More Related Videos
06:41Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
Related Concept Videos
Alzheimer's Disease: Treatment
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
Drugs Affecting Neurotransmitter Release or Uptake
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists